Integra Lifesciences Holdings Corp Sentiment Worsening on Low Stock Potential

May 17, 2018 - By Margaret Downey

Sentiment for Integra Lifesciences Holdings Corp (NASDAQ:IART)

Integra Lifesciences Holdings Corp (NASDAQ:IART) institutional sentiment decreased to 0.98 in Q4 2017. Its down -0.31, from 1.29 in 2017Q3. The ratio turned negative, as 88 investment professionals opened new or increased holdings, while 90 decreased and sold equity positions in Integra Lifesciences Holdings Corp. The investment professionals in our partner’s database reported: 70.22 million shares, up from 68.21 million shares in 2017Q3. Also, the number of investment professionals holding Integra Lifesciences Holdings Corp in their top 10 holdings was flat from 2 to 2 for the same number . Sold All: 20 Reduced: 70 Increased: 65 New Position: 23.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $5.25 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 78.16 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

The stock increased 0.38% or $0.24 during the last trading session, reaching $64.09. About 325,084 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 29.35% since May 17, 2017 and is uptrending. It has outperformed by 17.80% the S&P500.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on July, 25. They expect $0.60 earnings per share, up 33.33 % or $0.15 from last year’s $0.45 per share. IART’s profit will be $49.10M for 26.70 P/E if the $0.60 EPS becomes a reality. After $0.58 actual earnings per share reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts 3.45 % EPS growth.

Sector Gamma As holds 4.08% of its portfolio in Integra LifeSciences Holdings Corporation for 506,630 shares. Broadfin Capital Llc owns 330,600 shares or 2.59% of their US portfolio. Moreover, Champlain Investment Partners Llc has 2.52% invested in the company for 4.65 million shares. The California-based Falcon Point Capital Llc has invested 2.09% in the stock. Tributary Capital Management Llc, a Colorado-based fund reported 361,795 shares.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Ratings analysis reveals 33% of Integra Lifesciences’s analysts are positive. Out of 9 Wall Street analysts rating Integra Lifesciences, 3 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $5200 while the high is $7000. The stock’s average target of $57.63 is -10.08% below today’s ($64.09) share price. IART was included in 10 notes of analysts from January 2, 2018. The firm earned “Buy” rating on Wednesday, April 25 by Jefferies. JP Morgan maintained the stock with “Neutral” rating in Thursday, April 26 report. The company was maintained on Wednesday, February 28 by JMP Securities. The firm has “Neutral” rating given on Wednesday, April 11 by JP Morgan. Raymond James downgraded the stock to “Market Perform” rating in Tuesday, January 2 report. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Buy” rating by Oppenheimer on Thursday, March 29. Bank of America downgraded the stock to “Neutral” rating in Tuesday, January 2 report. The firm has “Hold” rating by Cantor Fitzgerald given on Wednesday, April 25.

More important recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: which released: “Integra LifeSciences Reports First Quarter 2018 Financial Results” on April 25, 2018, also published article titled: “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …”, published: “Integra LifeSciences Prices Public Offering of Common Stock” on May 09, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) was released by: and their article: “Integra LifeSciences Announces Proposed Public Offering of Common Stock” with publication date: May 09, 2018.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: